1 |
JAK2
💬
| [24] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | Ruxolitinib
Ruxolitinib
💬
|
Ruxolitinib
| [3] 60 60, 65, 228 💬
|
2 |
JAK2
💬
| [24] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | Tofacitinib
Tofacitinib
💬
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
|
3 |
JAK2
💬
| [24] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | Baricitinib
Baricitinib
💬
|
Baricitinib
| [13] 2 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
|
4 |
JAK2
💬
| [24] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis | Peficitinib
Peficitinib
💬
|
Peficitinib
| [1] 46 46 💬
|